For over three decades, K-RAS has been known as the holy grail of cancer targets, 28 one of the most frequently mutated oncogenes in cancer. Because the development 29 of conventional small molecule K-RAS inhibitors has been extremely challenging, K-30 RAS has been dubbed as an undruggable target, and only recently a mutation specific 31 inhibitor has reached clinical trials. Targeted protein degradation has emerged as a 32 new modality in drug discovery to tackle undruggable targets. However, no degrader 33 for K-RAS has been described thus far. Our laboratory has developed an Affinity-34 directed PROtein Missile (AdPROM) system for targeted proteolysis of endogenous 35 proteins through the ubiquitin proteasome system. Here, we show that we can achieve 36 degradation of endogenous K-RAS and H-RAS in different cell lines in a targeted 37 manner using our AdPROM system. Our findings imply that endogenous RAS proteins 38 can be targeted for proteolysis, thereby offering tantalising possibilities for an 39 alternative therapeutic approach to these so-called undruggable targets in cancer. 40 41 Keywords 42 High affinity binder, Ubiquitin proteasome system, UPS, Targeted proteolysis, 43 PROTAC 44 45 46 47 48 49 50 3 Background 51
4 targeting a cysteine in K-RAS G12C was developed to target this specific mutation 76
[13]. However, these barriers and failure to directly target RAS have prompted 77 researchers to explore targeting upstream regulators, or downstream effectors of RAS 78 proteins [1, 9, [14] [15] [16] , as well as altering levels of RAS protein, for example by inducing 79 targeted degradation of RAS [17] . 80
Most targeted protein degradation approaches harness the cellular proteolytic 81 pathways that naturally maintain proteostasis, with the ubiquitin-proteasome system 82 (UPS) being frequently exploited [18] . Protein degradation by the UPS is triggered by 83 conjugation of ubiquitin chains onto the target protein, which is achieved through a 84 sequential action of three enzymes: the ubiquitin-activating enzyme (E1), which 85 activates the carboxy-terminal glycine residue of ubiquitin in an ATP-dependent 86 manner; a ubiquitin-conjugating enzyme (E2), which conjugates the activated ubiquitin 87 to its active site cysteine; and a ubiquitin ligase (E3), which facilitates the transfer of 88 ubiquitin from E2 to primarily lysine residues on substrate proteins [19, 20] . Further 89 ubiquitylation on one or more lysine residues within ubiquitin then triggers 90 polyubiquitylation, followed by degradation by the proteasome [21] [22] [23] . Targeting RAS 91 for proteolysis relies on the engagement of the cellular proteolytic systems for its 92 ubiquitylation and degradation. In this context, it has been shown that the 93 heterobifunctional molecule dTAG-13, which recruits FKBP12F36V-tagged proteins of 94 interest (POIs) to the CRBN/CUL4A E3 ubiquitin ligase for their degradation, can 95 degrade FKBP12F36V-KRASG12V overexpressed in cell lines [17] . However, 96 FKBP12F36V itself can be targeted for ubiquitylation when using heterobifunctional 97 small molecule binders [24] . Therefore, it remains unclear, whether using dTAG13 on 98 FKBP12F36V-K-RAS results in the ubiquitination of K-RAS or FKBP12F36V. Such 99 information is not only key to evaluate proteolysis as a druggable approach for 100 7 All cells were cultured in humidified incubators at 37C and 5% CO2. A549, HEK293-150 FT, A375, A172 and SW620 cells were cultured in Dulbecco's modified Eagle's 151 medium (DMEM; Gibco) with 10% FBS (Sigma), 1% penicillin/streptomycin (Lonza) 152 and 2 mM L-glutamine (Lonza). HT-29, HPAFII and H460 cells were cultured in 153 RPMI1640 medium (Gibco), with the same supplements as DMEM. For retrovirus 154 production, 3.2 g pCMV-gag-pol, 2.2 g pCMV-VSV-G and 6 g of respective 155 pBabeD plasmids were co-transfected in roughly 70% confluent HEK293-FT cells 156 cultured on a 10-cm dish. Plasmids were mixed with 600 l Opti-MEM (Gibco) and 24 157 l of 1 mg/ml polyethyleneimine (Polysciences) dissolved in 25 mM HEPES pH 7.5. 158
The mixture was vigorously vortexed for 15 s and incubated for 20 min at room 159 temperature. The volume was adjusted to 10 ml with DMEM and added to FT cells. 160
After 24 h, medium was exchanged to DMEM or RPMI, depending on the target cell 161 growth medium. After an additional 24 h, the medium was harvested and filtered 162 through a 0.45 m Minisart syringe filter (Sartorius). The supernatant was added to a 163 plate of roughly 70% confluent target cells in a 1:10-1:4 dilution (in respective medium) 164
in the presence of 8 g/ml polybrene (Sigma). After 24 h, growth medium was 165 exchanged with fresh medium containing 2 g/ml puromycin, to select transduced 166 Cells were seeded in a 12-well dish onto cover slips and grown over night. The next 243 day, cells were washed twice in PBS and fixed for 10 minutes in 4% 244 formaldehyde/PBS (Sigma). Coverslips were washed in DMEM (Gibco) containing 10 245 mM HEPES followed by a 10 min incubation. Coverslips were washed in PBS and 246 permeabilised for 3 min in either 0.2% NP-40/PBS or 0.2% Triton X-100/PBS. 247
Coverslips were washed twice in PBS and blocked for 15 min in 3% BSA (Sigma) in 248 PBS. Primary antibody incubation was done for 1-2 h at room temperature at 249 11 appropriate antibody dilutions in blocking solution. Residual antibody was washed 250 away in 0.2% Tween/PBS (3x10 min). Secondary antibody incubation was done for 251 30 min at 1:300 antibody dilution in the dark. The same wash steps were repeated, 252 but the first wash contained DAPI (0.5-1 g in 10 ml). Finally, coverslips were dipped 253 in water, air dried and mounted on slides with Vectashield (Vector Laboratories). 254
Fluorescence signals were analysed on a Deltavision Widefield microscope (GE). 255
Images were deconvolved using the default settings of softWoRx Imaging software. 256 257
Cell Proliferation Assays 258
After trypsinization, live cell numbers were determined in a Neubauer haemocytometer 259
in the presence of trypan blue. Cell numbers were adjusted to 5000 cells per ml in the 260 respective growth medium. 5000 cells were added per well of a 12-well dish, and each 261 line was grown in triplicates. After 7 days, relative cell numbers were determined by 262 crystal violet staining. In short, cells were washed in PBS, fixed for 5 min in fixing buffer 263 (10% methanol, 10% acetic acid), washed in PBS again and incubated for 30-60 min 264 in crystal violet solution (0.5% crystal violet in 20% methanol). Plates were dipped in 265 tap water to remove stain and air dried overnight. Plates were scanned on a Licor 266 Odyssey using the 700 nm channel. Subsequently, 1 ml methanol was added to each 267 well and plates were incubated shaking for 30 min. Depending on the colour of 1 set 268 of cells, 100-200 l of supernatant was loaded in triplicate on a 96-well plate and 269 absorbance at 570 nm was measured in an Epoch microplate spectrophotometer 270 
Generation of a GFP-KRAS knock-in non-small cell lung cancer A549 cell line 286
The high degree of amino acid sequence similarity between the four RAS proteins, i.e. 287 K-RAS4A, K-RAS4B, H-RAS and N-RAS ( Fig. 1A) , and the subsequent difficulty in 288 generating selective antibodies against individual isoforms pose substantial 289 challenges in studying specific RAS proteins [32] . In order to explore targeted 290 proteolysis of K-RAS using the AdPROM system, we employed CRISPR/Cas9 291 technology to generate an A549 non-small cell lung carcinoma (NSCLC) cell line 292 harbouring a homozygous knock-in of green fluorescent protein (GFP) cDNA at the N-293 terminus of the native K-RAS gene (Fig. S1 ). As K-RAS4A and K-RAS4B are splice 294 variants differing only in their extreme C-terminus ( Fig. 1A) , this approach allowed us 295 to simultaneously tag both isoforms with GFP. The homozygous GFP knock-ins on 296 the native K-RAS locus (A549GFPKRAS) were verified by genomic sequencing (Fig. S1 ). 297
Moreover, by western blot analysis using both pan-RAS and K-RAS4B antibodies, the 298 appearance of higher molecular weight GFP-K-RAS species with a concurrent 299 disappearance of the native molecular weight K-RAS species was evident in the 300 A549GFPKRAS cell line compared to wild type (WT) A549 control cells (Fig. 1B) . The use 301 of a panRAS antibody resulted in the detection of two distinct bands in A549 WT cells 302 ( Fig.1B) . As the lower band remained intact in A549GFPKRAS cells, it most likely 303 corresponds to H-and/or N-RAS ( Fig. 1B ). However, in A549 cells we were unable to 304 detect any endogenous signals with commercially available H-RAS, N-RAS or K-305 RAS4A specific antibodies (listed in Methods section). By qRT-PCR, we showed that 306 levels of H-and N-RAS transcripts were slightly reduced in A549GFPKRAS cells 307 compared to WT A549 cells, while transcript levels of K-RAS were reduced by roughly 308 50% ( Fig. S2 ). We were able to efficiently immunoprecipitate GFP-K-RAS from 309 A549GFPKRAS but not WT A549 cell extracts (Fig. 1C) . 310
311
Recently, a number of RAS antibodies have been evaluated for selective recognition 312 of the different RAS proteins by Western blotting [32], but none of these have been 313 selective for use in immunofluorescence studies. Consequently, studies evaluating 314 subcellular distribution of RAS proteins have been restricted to overexpression 315 systems. Validation of A549GFPKRAS cells allowed us to investigate the sub-cellular 316 distribution of endogenous GFP-K-RAS driven by the native promoter. Endogenous 317 GFP-K-RAS displayed predominantly plasma membrane distribution, which was 318 confirmed by co-staining with P120 catenin, which is known to localise to the plasma 319 membrane [33] (Fig. 1D, Fig. S3 ). Additionally, we also observed some weak 320 cytoplasmic localisation of GFP-K-RAS. However, no co-localisation of GFP-K-RAS 321 was observed with mitochondrial marker ATPB [34] (Fig. 1D, Fig. S3 ). 322 323
Targeted degradation of GFP-K-RAS by the proteolytic AdPROM system 324
We sought to test whether endogenously expressed GFP-K-RAS protein in 325 A549GFPKRAS cells could be targeted for degradation by AdPROM [25, 26] . We have 326 previously shown that fusion of VHL to an aGFP16 nanobody recruits GFP-tagged 327 proteins, such as VPS34 and PAWS1, to the CUL2-RBX1 E3 ligase machinery for 328 target ubiquitination and subsequent proteasomal degradation [25] . Therefore, we 329 postulated that GFP-K-RAS could be recruited in a similar manner to the CUL2-RBX 330 complex for ubiquitination and degradation ( Fig. 2A) . Indeed, expression of VHL- understanding of the distribution of the cells within this population, we employed a flow 347 cytometric analysis based on GFP fluorescence. We employed gates to define a GFP-348 positive population based on the GFP-signal from untransduced A549GFPKRAS cells and 349 using WT A549 cells as a GFP-negative control (Fig. 2D ). In accordance with the 350
Western blot results (Fig. 2B ), 97% of cells expressing VHL-aGFP16 AdPROM 351 showed GFP-KRAS degradation compared to untransduced A549GFPKRAS cells ( Fig.  352 2D), which manifested in an overall reduction of GFP fluorescence of the single cell 353 population (Fig. 2E) . The remaining 3% of A549GFPKRAS cells produced GFP signal 354 comparable to untransduced GFP-positive-population, which could be due to low level 355
AdPROM expression within these cells (Fig. 2D) . In contrast, A549GFPKRAS cells 356 expressing VHL or aGFP16 alone were defined as GFP-positive at 99.3% or 99.8%, 357 respectively ( Fig. 2D, E) . 358
359

AdPROM mediated degradation of endogenous RAS proteins 360
The AdPROM-mediated degradation of GFP-K-RAS in A549GFPKRAS cells 361 demonstrated the prospect of targeted degradation of endogenous K-RAS. However, 362 the presence of the GFP-tag raised the possibility of ubiquitination occurring on the 363 GFP moiety, instead of on K-RAS. Therefore, we sought to explore whether we could 364 exploit the AdPROM system to degrade endogenous, unmodified K-RAS from A549 365 cells. At present, there are no reported high affinity, selective polypeptide binders of 366 K-RAS. However, we utilized an anti-H-RAS (aHRAS) monobody that was reported to 367 bind and immunoprecipitate both H-RAS and K-RAS, but not N-RAS [36] . Using this 368 monobody with a FLAG-tag, we showed that anti-FLAG immunoprecipitates (IPs) 369 could robustly coprecipitate both GFP-tagged and untagged K-RAS, as well as the 370 lower molecular weight protein representing the H-and/or N-RAS band but most likely 371
to be H-RAS [36] (Fig. 3A) . However, neither RAS protein was completely depleted 372 from flow-through extracts, suggesting incomplete immunoprecipitation (Fig. 3A) . In 373 contrast, anti-FLAG IPs from extracts expressing Flag-VHL control did not co-374 precipitate either protein (Fig. 3A) . 375 376 Next, we sought to investigate whether AdPROM consisting of VHL fused to aHRAS 377 monobody could target K-and H-RAS proteins for degradation. In A549GFPKRAS cells, 378 the expression of VHL-aHRAS resulted in a strong reduction of the GFP-K-RAS 379 protein levels when compared to untransduced, VHL or monobody alone controls (Fig.  380   3B) . However, the degradation induced by VHL-aHRAS AdPROM was slightly less 381 efficient than that achieved with the VHL-aGFP16 AdPROM (Fig. 3B ). Unlike VHL-382 aGFP16, VHL-aHRAS also reduced the protein levels corresponding to the H-RAS 383 and/or N-RAS band (Fig. 3B ). The loss in protein levels of endogenous H-RAS protein 384 caused by VHL-aHRAS AdPROM could be rescued by the Cullin neddylation inhibitor 385
MLN4924, suggesting that the degradation was mediated through CUL2-RBX E3 386 ligase machinery (Fig. 3C ). As expected, MLN4924 also stabilised endogenous HIF1 387 ( Fig. 3C ). We also assessed the relative abundance of GFP-K-RAS in mixed 388 populations of A549GFPKRAS cells transduced with VHL-aHRAS AdPROM in 389 comparison to controls by flow cytometry. We found that 77% of cells showed 390 degradation of GFP-K-RAS, as assessed by the shift of the GFP-positive gated 391 population towards the GFP-negative population (Fig. 3D ) and the overall reduction of 392 GFP-signal (Fig. 3E) . The remaining 23% of cells transduced with VHL-aHRAS were 393 seemingly unaffected in both positioning in the GFP-positive gate (Fig. 3D) , as well as 394 GFP intensity (Fig. 3E ). Transductions with VHL or aHRAS alone did not induce a 395 noticeable shift of the GFP population or GFP signal intensity ( Fig. 3D & E) . 396 397
Uneven retroviral transduction of cells could result in unequal expression of the 398
AdPROM constructs in different cells resulting in a mixed, divergent cell population, 399 which may account for the apparent uneven degradation of GFP-K-RAS through VHL-400 aHRAS. When we analysed these A549GFPKRAS mixed cell populations by 401 immunofluorescence for GFP signal, in untransduced and aHRAS-transduced control 402 cells, a predominant plasma membrane GFP-K-RAS signal was evident (Fig. 3F) . 403
Transduction of A549GFPKRAS cells with either VHL-aHRAS or VHL-aGFP16 AdPROM 404 produced a heterogenous population comprising cells with missing or severely 405 attenuated GFP signal, and cells with intact GFP-K-RAS staining pattern, localizing 406 mainly to the plasma membrane ( Fig. 3F) . In contrast, we noticed a slight increase in 407 perinuclear GFP-K-RAS signal in cells transduced with the aHRAS monobody alone 408 ( Fig. 3F ). Interestingly, we detected that the majority of the monobody itself was in the 409 nucleus ( Fig. S4) , while we were unable to consistently detect signals for the AdPROM 410 fusion proteins by anti-FLAG immunofluorescence (Fig. S4) . 411
412
We also tested the degradation of endogenous K-and H-RAS in WT A549 cells with 413 VHL-aHRAS AdPROM. The transduction of cells with VHL-aHRAS resulted in a 414 substantial reduction in apparent levels of both K-RAS (upper band) and H-RAS (lower 415 band) proteins as detected by the pan-RAS antibody compared to untransduced 416 controls ( Fig. 3G ). Unlike in A549GFPKRAS cells (Fig. 3B) , WT cells transduced with 417
VHL-aGFP16 AdPROM did not have any noticeable effect on K-RAS and H-RAS 418
protein levels relative to untransduced cells (Fig. 3G) , further validating the targeted 419 nature of RAS degradation by AdPROM. Cells transduced with the aHRAS monobody 420 alone led to a slight increase in abundance of both K-RAS and H-RAS proteins 421 compared to untransduced controls (Fig. 3G) . We sought to explore whether targeted 422 degradation of K-and H-RAS proteins from WT A549 cells using the VHL-aHRAS 423
AdPROM, and GFP-K-RAS from A549GFPKRAS cells using the VHL-aGFP16 AdPROM 424 would impact cell proliferation. No significant differences in proliferation could be 425 observed for either WT A549 or A549GFPKRAS cells following AdPROM-mediated 426 degradation of the respective RAS proteins compared to controls after 7 days, as 427 
Expansion of the RAS-targeting AdPROM system in different cell lines 434
Having demonstrated for the first time that the VHL-aHRAS AdPROM system could 435 target endogenous H-and K-RAS for degradation in A549 cells, we sought to explore 436
whether the system would work in other cell lines. First, we compared different cell 437 lines for their endogenous RAS protein expression ( Fig. 4A) relative to A549 cells. All 438 cells tested displayed K-RAS protein expression similar to or slightly lower than A549 439 cells. SW620 cells, which harbour the G12V mutation on K-RAS [37], displayed similar 440 levels of expression to A549 cells, however, we noticed that K-RAS in this cell line 441 produced a slight but noticeable molecular weight shift, when probed with panRAS 442 and K-RAS4B antibodies (Fig. 4A ). Protein levels corresponding to the lower H-and/or 443 N-RAS band were similar in all lines tested but overall much lower in intensity than 444 that seen for K-RAS. We tested the ability of VHL-aHRAS AdPROM to degrade RAS 445 proteins from HT-29 and SW620 cells. In HT-29 cells, which express WT RAS proteins 446 but harbour the activating BRAF V600E mutation [38] , only the levels of H-RAS but 447 not K-RAS proteins were reduced by VHL-aHRAS AdPROM compared to controls 448 ( Fig. 4B, left panel) . The proliferation of HT-29 cells was only reduced by about 50% 449 by the aHRAS monobody alone ( Fig. 4C and D) , while the VHL-aHRAS and VHL-450 aGFP16 constructs reduced growth to a lesser extent (Fig. 4D, left panel) . For SW620 451 cells, which harbour the G12V mutation of K-RAS, we noticed a high K-RAS signal to 452 H-/N-RAS signal ratio, as the latter was barely detectable (Fig. 4B, right panel) . We 453 observed stabilization of K-RAS with the aHRAS monobody alone, while VHL-aHRAS 454 failed to degrade K-RAS compared to controls. Interestingly, both the aHRAS 455 monobody alone and the VHL-aHRAS AdPROM but not VHL-aGFP16 AdPROM were 456 able to reduce the proliferation of SW620 cells significantly by about 50% (Fig. 4C In this report, we demonstrate that endogenous K-RAS and H-RAS proteins can be 461 targeted for degradation using the proteolytic AdPROM system. RAS proteins have 462 remained elusive targets for anti-cancer therapies, primarily due to their undruggability 463 demonstrating here that endogenous RAS proteins can be targeted for proteolysis 480 through the UPS, informs that small molecules targeting RAS proteins for degradation 481 is a viable option for intervention. Furthermore, our A549GFPKRAS cells provide an 482 excellent high throughput screening platform to test the efficacy of such molecules. 483
However, targeted delivery of polypeptide binders of RAS proteins or the proteolytic 484
AdPROM system into RAS-dependent cancer cells remains challenging and therefore 485 currently offers limited therapeutic potential. 486
487
One difficulty in the study of RAS proteins is the absence of robust reagents to reliably 488 detect specific RAS proteins at the endogenous levels, especially by 489 immunofluorescence [32] . Often, overexpression of GFP-tagged or other epitope-490 tagged K-RAS has been employed to investigate RAS localization [36, 49, 50] . 491 Therefore, our homozygous A549GFPKRAS NSCLC cell line generated using 492 CRISPR/Cas9, notwithstanding the potential caveats of GFP-tagging, has allowed us 493 to not only assess localization of endogenously driven GFP-K-RAS protein but its 494 mobility shift has allowed us to test the utility of panRAS and K-RAS antibodies in 495 detecting K-RAS by Western blotting. Beyond the plasma membrane localisation, we 496 observed additional disperse cytoplasmic signals of endogenous GFP-K-RAS, but no 497 mitochondrial localisation. When overexpressed, K-RASG12V has been implied to be 498 transported into mitochondria, leading to alterations of membrane potential, a 499 decrease in respiration and an increase in glycolysis [51] . Potential compartments for 500 the observed cytosolic signal for K-RAS could be Golgi, as seen for H-and N-RAS 501
[52], which could correspond to K-RAS4A signal, or Endoplasmic Reticulum. However, 502 this remains to be verified. 503
504
While the VHL-aGFP AdPROM was very effective at selectively degrading GFP-K-505 RAS from A549GFPKRAS cells, the VHL-aHRAS AdPROM degraded endogenous H-506 and K-RAS with mixed efficacy in different cell lines. In developing the aHRAS 507 monobody, the authors noted a difference in downstream behaviours of H-and K-RAS 508 upon monobody binding, such as K-RAS, but not H-RAS being displaced from the 509 membrane, or the mutant K-RAS, but not mutant H-RAS interaction with RAF being 510 disturbed by monobody binding [46] . The full determinants of interaction between the 511 aHRAS monobody and different H-and K-RAS mutants or any post-translationally 512 modified forms remain poorly defined. It is perhaps the differences in affinity between 513 the RAS proteins and the aHRAS monobody that define how robustly or poorly VHL-514 aHRAS can degrade different RAS proteins. Nonetheless, our study proves that any 515 high-affinity polypeptide binders that can selectively bind specific RAS proteins or 516 mutants can be packaged with VHL-AdPROM in order to target specific RAS proteins 517 for proteasomal degradation. We also noted that aHRAS monobody alone resulted in 518 a marked stabilization of both H-RAS and K-RAS in multiple cells ( could be due to the unusual size shift of K-RAS in these cells, possibly caused by a 534 post-translational modification or a mutation that might allow binding to aHRAS 535 monobody but prevent ubiquitylation by the VHL-AdPROM, although this needs to be 536 defined further. Many RAS-dependent cell proliferation assays employ anchorage-537 independent 3D cultures. For example, the K-RASG12C drug ARS-1620 was shown to 538 be effective at inhibiting RAS-dependent cell proliferation in 3D cultures but not in 2D 539
cultures [40] . In order to assess the effects of AdPROM-mediated degradation of H-540 /K-RAS on proliferation robustly, it will be essential to first obtain polypeptide RAS 541 binders that bind to specific RAS proteins with high affinity and then use them in RAS-542 dependent cell lines using 3D proliferation assays. 543
544
Recently two allosteric small molecule binders were described for K-RAS with low 545 micromolar and nanomolar binding affinities [42, 43] . It would be important to test these 546 binders' capabilities as K-RAS targeting warheads in a PROTAC approach. In this line, 547 a re-evaluation of RAS binding molecules, with or without inhibitory function, might 548 prove successful for PROTAC designs. 549 550
Conclusion 551
Our findings demonstrate clearly that endogenous RAS proteins can be targeted for 552 proteasomal degradation by employing the AdPROM system. The system is not only 553 suitable for studying the functions of these RAS proteins but also unequivocally 554 informs that targeted proteolysis of endogenous K-RAS is a viable strategy to target 
